Patents by Inventor Lawrence Black

Lawrence Black has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20220363678
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: November 24, 2020
    Publication date: November 17, 2022
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei Zhang, Yunsong Tong, Charles W. Hutchins, SeungWon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20220106281
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: December 1, 2020
    Publication date: April 7, 2022
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei Zhang, Yunsong Tong, Charles W. Hutchins, SeungWon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20210269399
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: September 30, 2020
    Publication date: September 2, 2021
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei Zhang, Yunsong Tong, Charles W. Hutchins, SeungWon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20210113532
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: May 28, 2020
    Publication date: April 22, 2021
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, SeungWon Chung, Michael J. Dart
  • Modulators of the integrated stress pathway
    Patent number: 10913727
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 9, 2021
    Assignee: AbbVie Inc.
    Inventors: Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • Modulators of the integrated stress pathway
    Patent number: 10864196
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 15, 2020
    Assignees: Calico Life Sciences, LLC, AbbVie Inc.
    Inventors: Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20200361941
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 19, 2020
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Yunsong Tong, Lawrence A. Black, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, SeungWon Chung, Zhaoming Xiong, Ramzi Farah Sweis, Michael J. Dart, Brian S. Brown, Kathleen J. Murauski
  • Modulators of the integrated stress pathway
    Patent number: 10836725
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: November 17, 2020
    Assignee: AbbVie Inc.
    Inventors: Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20200345727
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 5, 2020
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Marina Pliushchev, Yunsong Tong, Lawrence A. Black, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, SeungWon Chung, Ramzi Farah Sweis, Michael J. Dart, John T. Randolph, Kathleen J. Murauski
  • PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL
    Publication number: 20200039930
    Abstract: The present invention relates to proline amide compounds and their azetidine derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of the 5-HT2C receptor, and processes for preparing such compounds and compositions.
    Type: Application
    Filed: March 20, 2018
    Publication date: February 6, 2020
    Inventors: Gisela Backfisch, Margaretha Henrica Maria Bakker, Lawrence Black, Wilfried Braje, Karla Drescher, Thomas Erhard, Andreas Haupt, Carolin Hoft, Andreas Kling, Viktor Lakics, Helmut Mack, Frank Oellien, Ana Lucia Relo
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20190194135
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: May 5, 2017
    Publication date: June 27, 2019
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20190142806
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 16, 2019
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20190144440
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 16, 2019
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • MODULATORS OF THE INTEGRATED STRESS PATHWAY
    Publication number: 20190135772
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 9, 2019
    Inventors: Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • TERTIARY AMIDES AND METHOD OF USE
    Publication number: 20190119200
    Abstract: Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 25, 2019
    Inventors: Lawrence A. Black, William H. Bunnelle, Da Chen, Bruce Clapham, David A. Degoey, Xiangjun Deng, Liqiang Fu, Lisa A. Hazelwood, Linglong Kong, Qingyu Lang, Chih-Hung Lee, Mingfeng Li, Greta L. Lundgaard, Meena V. Patel, Ruihong Tao, Lin Zhang, Qingwei Zhang, Qiangang Zheng, Wei Zhu
  • TRPV3 MODULATORS
    Publication number: 20180243298
    Abstract: A compound of Formula (I) having efficacy for the treatment or prevention of conditions and disorders related to TRPV3 activity, e.g. pain, atopic dermatitis, eczema, itch or psoriasis, is disclosed. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Application
    Filed: March 30, 2016
    Publication date: August 30, 2018
    Inventors: Lawrence Black, Brian S. Brown, Bruce Clapham, Marlon D. Cowart, Michael J. Dart, Ramin Faghih, Jennifer Frost, Arthur R. Gomtsyan, Philip R. Kym, Huaqing Liu, Robert G. Schmidt, Lei Shi, Anurupa Shrestha, Kevin Sippy
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20180030033
    Abstract: The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: October 4, 2017
    Publication date: February 1, 2018
    Inventors: Hervé GENESTE, Sean Colm TURNER, Michael OCHSE, Karla DRESCHER, Lawrence A. BLACK, Katja JANTOS
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 9790203
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: October 17, 2017
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Hervé Geneste, Sean Colm Turner, Michael Ochse, Karla Drescher, Lawrence A. Black, Katja Jantos
  • Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors
    Patent number: 9657034
    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: May 23, 2017
    Assignees: AbbVie Deuschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Sean Turner, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Lawrence Black, Katja Jantos
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20160137668
    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: January 18, 2016
    Publication date: May 19, 2016
    Inventors: Hervé GENESTE, Michael OCHSE, Karla DRESCHER, Sean TURNER, Berthold BEHL, Loic LAPLANCHE, Jürgen DINGES, Clarissa JAKOB, Lawrence BLACK